Advertising peptide therapy on Google or Meta is possible — but the rules are specific to each compound, each platform, and your certification status. Running ads without understanding the risk spectrum results in account suspensions, ad disapprovals, and FTC exposure. Here is the complete breakdown of what each peptide tier allows, what triggers a ban, and how to structure compliant campaigns.
The three-tier peptide advertising framework
Peptides do not all carry the same advertising risk. The FDA's regulatory category is the first filter, but platform policies add another layer that does not map cleanly onto regulatory status. Before running any peptide-related advertising, every clinic needs to know which tier each compound falls into.
Tier 1 — Low risk: Advertise with standard care
These compounds have the cleanest regulatory history and the most direct path to compliant advertising:
- Sermorelin — Former FDA-approved drug (Geref); never placed in Category 2; compoundable under 503A with USP monograph; can be named in Google ads with LegitScript certification
- Ipamorelin — Removed from Category 2 in September 2024; widely compounded by 503A pharmacies; no current enforcement action against compounders
- CJC-1295 (without DAC) — Also removed from Category 2 in September 2024; commonly stacked with ipamorelin; same compliance posture
- Topical cosmetic peptides (GHK-Cu serum, Matrixyl, Argireline) — Regulated as cosmetics, not drugs; no prescription required; standard advertising rules apply
- NAD+ — Not a peptide but frequently bundled with peptide protocols; widely available; no Category 2 status; marketable with wellness framing
Tier 2 — Medium risk: Can advertise with care and certification
These compounds have sufficient regulatory footing to market but require careful copy and ideally LegitScript certification to scale on paid channels:
- PT-141 (Bremelanotide) — FDA-approved as Vyleesi; compounded versions exist in a gray zone; marketed carefully under sexual health framing with explicit reference to the approved drug context
- Thymosin Alpha-1 — Removed from Category 2 in September 2024; clinical use in immune support contexts; no COVID-19 treatment claims
- CJC-1295 (with DAC) — Chemically distinct from the without-DAC version; different regulatory status; confirm with your pharmacy which version they produce before making any marketing claims
Tier 3 — High risk: Organic content only, no paid ads
These compounds remain on the Category 2 restricted list. They cannot be legally compounded, advertised as a current service, or named in paid ad copy under any circumstances:
- BPC-157 — Category 2; PCAC review July 23–24, 2026; largest patient demand in the peptide category
- TB-500 — Category 2; PCAC review July 2026; also on WADA's 2025 Prohibited List
- MOTS-c — Category 2; PCAC review July 2026; strong longevity and metabolic research interest
- GHRP-2, GHRP-6, Semax, KPV, LL-37 — Category 2; PCAC timeline varies by compound
Google Ads: what gets your account suspended
Google's Healthcare and Medicines policy classifies any business involving physician prescribing and pharmacy compounding as a "Prescription Drug Service." This classification requires LegitScript Healthcare certification to advertise. Without it, ads for these services will be disapproved or the account flagged for review.
The specific triggers that prompt immediate disapproval or account action:
- Naming a Category 2 compound anywhere in ad copy or on the landing page linked from the ad
- Keywords referencing compounding or injections of specific compounds: "buy peptides," "[compound] injection," "[compound] therapy"
- Disease treatment claims: "heal your tendons," "treat leaky gut," "increase testosterone" — these are unapproved drug claims on an uncertified account
- Landing pages that list specific compounds for purchase or inquiry, even if the ad copy itself is clean
What Google Ads allows for peptide clinics without LegitScript certification: general wellness and longevity positioning ("longevity medicine clinic," "anti-aging clinic [city]"), benefit-oriented copy without compound names ("optimize recovery," "personalized wellness protocols"), and ads driving to educational content rather than service pages. LegitScript Healthcare certification costs $1,000 to $4,000 for the initial application and takes 4 to 8 weeks. For any clinic serious about scaling patient acquisition for Tier 1 and Tier 2 peptide services, this investment is the prerequisite to operating without a ceiling on paid search reach.
Meta (Facebook and Instagram): the additional layer
Meta requires the same LegitScript certification as Google for prescription-adjacent services, plus has its own policy layer enforced primarily by algorithm rather than manual review. This creates a different failure mode: ads can run initially and then be taken down retroactively when the system flags the content — sometimes weeks into a campaign.
Meta-specific triggers beyond the Google policy list:
- Before-and-after imagery. Meta's computer vision systems flag transformation photos. This includes body composition changes, wound healing images, and other visual outcome content common to peptide clinics.
- Second-person health condition copy. "Are you struggling with low energy?" or "Do you suffer from slow recovery?" triggers Meta's health and wellness ad restrictions even when the underlying product is not a named drug.
- Health-implied audience names. Custom audiences named with health terms — "Peptide_Inquiry," "TRT_Leads" — can be disabled without warning.
- 2025 conversion tracking restrictions. Meta now classifies most health and wellness brands into a restricted category that limits optimization to leads and link clicks rather than appointment bookings. Structure ad objectives accordingly.
What works on Meta for peptide clinics: lifestyle imagery showing active, vital patients in everyday contexts (not clinical before-and-after); lead generation formats driving to free consultations rather than compound-specific service pages; brand awareness content that builds recognition before the conversion ask; boosted organic educational posts that educate without making direct service claims.
The organic channel exception
Platform advertising policies apply to paid placements. Organic content — Instagram posts, Facebook posts, blog content on your own website — operates under different rules. Community Standards for Meta and quality content guidelines for Google are more permissive for educational organic content than the advertising policies governing paid placements.
This creates the primary content strategy for Tier 3 compounds: build organic authority through educational content about BPC-157, TB-500, and other Category 2 compounds now. Use that organic authority to capture the search demand that will spike post-PCAC. Then convert that organic patient traffic with paid ads once the regulatory status changes and LegitScript certification is in place.
Complete risk matrix
| Compound | Google Ads (certified) | Google Ads (uncertified) | Meta (certified) | Organic content |
|---|---|---|---|---|
| Sermorelin | ✅ Can name | ❌ Avoid by name | ✅ Can name | ✅ Full discussion |
| Ipamorelin | ✅ Can name | ❌ Avoid by name | ✅ Can name | ✅ Full discussion |
| CJC-1295 (no DAC) | ✅ Can name | ❌ Avoid by name | ✅ Can name | ✅ Full discussion |
| PT-141 | ⚠️ With care | ❌ Avoid | ⚠️ With care | ✅ With regulatory caveats |
| BPC-157 | ❌ Never | ❌ Never | ❌ Never | ✅ Educational only |
| TB-500 | ❌ Never | ❌ Never | ❌ Never | ✅ Educational only |
| MOTS-c | ❌ Never | ❌ Never | ❌ Never | ✅ Educational only |
Frequently Asked Questions
Do I need LegitScript certification to run any peptide ads?
For general wellness and longevity clinic ads that do not name specific compounds or make prescription drug claims, certification is not required. For ads that name specific compoundable peptides — even Tier 1 compounds like sermorelin or ipamorelin — LegitScript certification is required to run on Google and Meta without account suspension risk. The certification process costs $1,000 to $4,000 and takes 4 to 8 weeks.
What happens if I name BPC-157 in a Google ad?
The ad will be disapproved and may trigger a policy review of your entire account. BPC-157 is a Category 2 compound that cannot be legally compounded or offered as a clinical service, meaning advertising it as a current service violates both Google's Healthcare policy and FDA drug advertising rules. Build organic authority around BPC-157 through educational content rather than paid placements until the PCAC ruling changes its status.
Can I boost organic posts about specific peptides on Instagram?
Boosting an organic post converts it into a paid ad, subjecting it to the same advertising policies as a directly created ad. An organic post about BPC-157 that is performing well as organic content should not be boosted — it will likely be rejected when it enters the paid review system. Keep organic educational content as organic; reserve paid placements for compliant content aligned with current regulatory status.
What ad copy is safe for Google Ads without LegitScript certification?
Benefit-oriented copy without compound names or disease treatment claims: "Personalized longevity protocols," "Physician-supervised wellness optimization," "Anti-aging medicine consultation — [city]." Drive these ads to educational landing pages or consultation booking pages rather than product pages listing specific compounds. The consultation can then address specific compounds under the physician-patient relationship.
How does the July 2026 PCAC ruling affect advertising?
A favorable PCAC ruling on BPC-157, TB-500, and MOTS-c would move them toward Category 1 status, allowing legal compounding under physician prescription. Clinics could then advertise these compounds with LegitScript certification — the same compliance pathway available today for sermorelin and ipamorelin. Platform policies typically lag regulatory changes by months, so certification should be obtained before the ruling so it is in place when advertising becomes possible.
What is the FTC exposure risk for peptide marketing claims?
The FTC controls what health claims can be made about any product or service. The core rule: you cannot make therapeutic claims — treating, curing, or preventing a disease — for unapproved drugs without adequate substantiation. For Category 2 compounds, any claim implying current human therapeutic benefit carries FTC exposure on top of FDA drug marketing violations. For Tier 1 compounds, wellness and optimization claims ("support healthy aging," "optimize growth hormone levels") carry lower risk than disease treatment claims.